AtaiBeckley (ATAI) Income from Non-Controlling Interests (2020 - 2026)
AtaiBeckley's (ATAI) quarterly Income from Non-Controlling Interests came in at -$20000.0 in Q1 2026, up 41.18% year-on-year from -$14166.7 in Q1 2025, and up 41.18% quarter-over-quarter from -$34000.0 in Q1 2025.
AtaiBeckley (ATAI) Income from Non-Controlling Interests (2020 - 2026) Analysis & Trends
AtaiBeckley (ATAI) has 6 years of Income from Non-Controlling Interests data on file, last reported at -$24000.0 in Q3 2025.
- For the quarter ending Q3 2025, Income from Non-Controlling Interests rose 4.0% year-over-year to -$24000.0; the trailing twelve-month figure through Sep 2025 stood at -$108000.0 (up 93.24% YoY), and the FY2024 full-year result was -$780000.0, up 78.75% from the prior year.
- Income from Non-Controlling Interests advanced to -$20000.0 in Q1 2026 per ATAI's latest filing, from -$34000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at -$20000.0 in Q1 2026 and bottomed at -$34000.0 in Q1 2025.
- A 5-year average of -$615666.7 and a median of -$677000.0 in 2022 frame the typical range for Income from Non-Controlling Interests.
- Across the five-year window, Income from Non-Controlling Interests sank 48500.0% in 2021 and jumped 97.14% in 2024, its largest moves.
- Tracing ATAI's Income from Non-Controlling Interests over 5 years: stood at -$4.4 million in 2021, then soared by 62.74% to -$1.6 million in 2022, then surged by 48.11% to -$850000.0 in 2023, then surged by 96.12% to -$33000.0 in 2024, then rose by 27.27% to -$24000.0 in 2025.
- Business Quant data shows ATAI's Income from Non-Controlling Interests at -$24000.0 in Q3 2025, -$17000.0 in Q2 2025, and -$34000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | - |
| 2 | Nanobiotix | 1,911.83 Bn | 1,911.77 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.62 Bn | 466.83 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.98 Bn | 61.22 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.75 Bn | 50.57 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | - |
| 10 | AtaiBeckley | 1.56 Bn | 1.56 Bn | - | -24,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20,000.00 |
| Sep 30, 2025 | -24,000.00 |
| Jun 30, 2025 | -17,000.00 |
| Mar 31, 2025 | -34,000.00 |
| Mar 31, 2025 | -34,000.00 |
| Dec 31, 2024 | -33,000.00 |
| Sep 30, 2024 | -25,000.00 |
| Jun 30, 2024 | -57,000.00 |
| Mar 31, 2024 | -665,000.00 |
| Dec 31, 2023 | -850,000.00 |
| Sep 30, 2023 | -873,000.00 |
| Jun 30, 2023 | -729,000.00 |
| Mar 31, 2023 | -1.22 Mn |
| Dec 31, 2022 | -1.64 Mn |
| Sep 30, 2022 | -1.81 Mn |
| Jun 30, 2022 | -891,000.00 |
| Mar 31, 2022 | -689,000.00 |
| Dec 31, 2021 | -4.40 Mn |
| Sep 30, 2021 | -484,000.00 |
| Mar 31, 2021 | 3.36 Mn |